// App-Quantinova.ai

9536 : Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.

Researchers

Presenter

  • James M. G. Larkin

Principal Investigators

  • Antoni Ribas

  • Keith Flaherty

  • Grant A. McArthur

  • Paolo Antonio Ascierto

  • Brigitte Dreno

  • Karl D. Lewis

  • Paul B. Chapman

  • Edward Francis Mckenna

  • Qian Zhu

  • Yong Mun

  • Axel Hauschild

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Massachusetts General Hospital, Boston, MA

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • Nantes University Hospital, Nantes, France

  • University of Colorado Cancer Center, Aurora, CO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Genentech, Inc., South San Francisico, CA

  • Genentech, Inc., South San Francisico, CA

  • University Hospital Schleswig-Holstein, Lubeck, Germany

Locations

  • Italy

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Cobimetinib

  • Vemurafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved